参麦注射液治疗急性心肌梗死的疗效及对患者心肌损伤的影响

目的 探究参麦注射液治疗急性心肌梗死患者的临床疗效以及对血清超敏C反应蛋白（hs-CRP）、N端B型利钠肽前体（NT-proBNP）、心肌损伤标志物的影响。方法 选取2017年6月~2018年12月我院治疗的急性心肌梗死患者86例作为研究对象，按照随机数字表法分为观察组和对照组，每组43例。对照组给予常规西药治疗，观察组在对照组基础上加用参麦注射液治疗，比较两组治疗前后血清hs-CRP、NT-proBNP、心肌损伤标志物水平、临床疗效、心血管不良事件（MACE）发生情况。结果 治疗后，观察组hs-CRP、NT-proBNP水平低于对照组（10.92±1.65）mg/L vs（18.39±3.03）mg/L]、（234.41±28.34）ng/L vs（314.65±36.14）ng/L]，差异有统计学意义（P＜0.05）。观察组AST、CK-MB及MYO水平低于对照组（31.17±3.96）U/L vs（43.86±7.52）U/L]、（6.18±1.02）ng/ml vs（10.34±1.66）ng/ml]、（38.42±7.61）ng/ml vs（56.19±10.12）ng/ml]，差异有统计学意义（P＜0.05）。观察组总有效率为90.70%，高于对照组的72.09%，差异有统计学意义（P＜0.05）。两组MACE发生率比较，差异无统计学意义（P＞0.05）。结论 参麦注射液有助于降低心肌梗死患者hs-CRP和NT-proBNP水平，改善患者心肌受损情况，提高临床疗效，安全可靠。

Effect of Shenmai Injection on Acute Myocardial Infarction and its Effect on Myocardial Injury

Objective To explore the clinical efficacy of Shenmai injection in the treatment of patients with acute myocardial infarction and the effects of serum high-sensitivity C-reactive protein (hs-CRP), N-terminal B-type natriuretic peptide precursor (NT-proBNP), and myocardial injury markers.Methods 86 patients with acute myocardial infarction treated in our hospital from June 2017 to December 2018 were selected as the study subjects. According to the random number table method, they were divided into observation group and control group, with 43 cases in each group. The control group was treated with conventional western medicine. The observation group was treated with Shenmai injection on the basis of the control group.Serum hs-CRP, NT-proBNP, myocardial injury marker levels, clinical efficacy, and cardiovascular adverse events (MACE) were compared before and after treatment.Results After treatment, the levels of hs-CRP and NT-proBNP in the observation group were lower than those in the control group (10.92±1.65) mg/L vs (18.39±3.03) mg/L], (234.41±28.34) ng/L vs (314.65±36.14) ng / L], the difference was statistically significant (P<0.05). The AST, CK-MB and MYO levels in the observation group were lower than those in the control group (31.17±3.96) U/L vs (43.86±7.52) U/L], (6.18±1.02) ng/ml vs (10.34±1.66) ng /ml], (38.42±7.61) ng/ml vs (56.19±10.12) ng/ml], the difference was statistically significant (P<0.05). The total effective rate of the observation group was 90.70%, which was higher than that of the control group 72.09%,the difference was statistically significant (P<0.05). There was no significant difference in the incidence of MACE between the two groups (P>0.05). Conclusion Shenmai injection can help to reduce the levels of hs-CRP and NT-proBNP in patients with myocardial infarction, improve myocardial damage, improve clinical efficacy, and be safe and reliable.